PVRI 2023/24 Digital: Breaking barriers in pulmonary hypertension

Next session:

13 March 2024

  • days
  • Hours
  • Minutes

PVRI 2023/24 Digital is a monthly webinar series of cutting edge science

We are delighted to introduce our new webinar series, PVRI 2023/24 Digital, launching November 2023. The series follows the success of our PVRI 2021/22 series and has been developed by Dr Patricia Thistlethwaite MD, PhD, University of California San Diego.

 

The monthly webinars will take place on the second Wednesday of each month at 15:00 BST/GMT and will feature keynote talks from senior experts in the field as well as young investigators. In addition to our in-person meetings and symposia, this series will enable us to connect with our worldwide community, but also allow us to continue to explore and discuss important new research. During the live sessions, there will be ample time set aside for Q&A to encourage active participation from our audience. 

Scientific programme

Enhancing drug development for paediatric pulmonary hypertension: an integrative perspective

14 February 2024, 3PM GMT

Presentations:

  • Clinical challenges in developing drug therapies for children with pulmonary hypertension Rolf Berger 
  • Challenges related to drug approval for children with pulmonary hypertension – regulatory perspective Christine Garnett 
  • Challenges facing pharmaceuticals in drug development for paediatric pulmonary hypertension Sylvia Nikkho 
  • Utility of paediatric registries for the characterization of pulmonary hypertensive phenotypes Maria Jesus del Cerro 

Ion channels: pathogenic role and therapeutic intervention in pulmonary arterial hypertension

13 March 2024, 3PM GMT

Presentations:

  • Mechanosensitive cation channels in the pulmonary vascular wall in pulmonary arterial hypertension Jason Yuan 
  • Proton exchangers in pulmonary smooth muscle cells in pulmonary arterial hypertension Larissa Shimoda 
  • Pathophysiologic role of mutant potassium channels in pulmonary hypertension Angel Cogolludo 
  • TRPV4 activity in lung microvascular endothelial cells in PAH Karthik Suresh

Single cell transcriptional profiling in lung health and pulmonary arterial hypertension

10 April 2023, 3PM BST

Presentations:

  • Update on the human lung RNAseq atlas
  • Unsupervised transcriptomic profiling of whole blood shows biologic heterogeneity in iPAH Allan Lawrie 
  • Cellular landscape atlas of pulmonary endarterectomy tissue using single cell RNAseq
  • Single cell RNAseq identifies cellular abnormalities in rodent models of pulmonary hypertension Jason Hong 
  • Single-cell transcriptomic profiles of pulmonary artery endothelial cells in health and pulmonary arterial hypertension. 

Chromosome dynamics in pulmonary hypertension: mechanism and new treatments

8 May 2024, 3PM BST

Presentations:

  • Chromatin remodelling and enhancer distance in pulmonary arterial hypertension Kurt Stenmark 
  • Teleomere modulation in pulmonary hypertension 
  • Intergenic DNA mutations drive the development of pulmonary arterial hypertension
  • Chromosomal aberrations in pulmonary arterial hypertension Micheala Aldred 

Are mitochondria the instigator of pulmonary arterial hypertension?

12 June 3PM BST

Presentations:

  • Cell-to-cell transport of mitochondria as the cause of pulmonary vascular disease
  • Mitochondrial transplantation as treatment for pulmonary arterial hypertension
  • SNPs for sirtuin3 and uncoupling protein2 are causal of pulmonary arterial hypertension and diabetes disease severity
  • Therapeutic efficacy and mechanisms of Drpitor1a in pulmonary arterial hypertension.
  • Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with pulmonary hypertension

More webinars to be announced soon!

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg